Shares of Precipio, Inc. [NASDAQ: PRPO] skyrocketed 40.35% during the trading session of Monday. The strong performance of the firm has highlighted the positive sentiments of the investors after the firm disclosed that it has successfully rolled out its COVID-19 rapid antibody test.
The rapid antibody test of the firm tests for both IgG & IgM antibodies, on the business platform of Amazon.com. Furthermore, Precipio possessed special rights to disseminate this product on the platform of Amazon.
Shares of Precipio soared 41.76% as it gained +0.83 during the tarding session of the firm. The firm has reported the tarding volume of 38.44 million as compared to the average volume of 605.95K. PRPO has total market capitalization of $34.31 million at the time of writing.
COVID-19 Rapid Antibody Test
The antibody test is the 20-minute test. It is built in the USA by Nirmidas Biotech, of California. It is the first US-based test to get EUA by the FDA for point-of-care. Furthermore, it has been disclosed that this product is accessible to people on Amazon’s website.
Purpose of COVID-19 Antibody Test
The main purpose of the COVID-19 antibody test is to identify whether the person develop antibodies or not after the person has been exposed to the virus, or has been vaccinated.
Additionally, this antibody has two main benefits. Firstly, the person will be able to know whether he has antibodies or not. Lastly, individuals who have been vaccinated will be able to know whether the vaccination was successful. Moreover, they will be able to know if the antibodies measured have persisted over time.